Abstract
Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Letters in Drug Design & Discovery
Title: Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient
Volume: 8 Issue: 2
Author(s): Leonard Amaral, Marta Martins and Miguel Viveiros
Affiliation:
Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine
Abstract: Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.
There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Export Options
About this article
Cite this article as:
Amaral Leonard, Martins Marta and Viveiros Miguel, Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient, Letters in Drug Design & Discovery 2011; 8 (2) . https://dx.doi.org/10.2174/157018011794183860
DOI https://dx.doi.org/10.2174/157018011794183860 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry Development and Optimization of Dual Drugs (Isoniazid and Moxiflox-acin) Loaded Functional PLGA Nanoparticles for the Synergistic Treatment of Tuberculosis
Current Drug Delivery Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Substance P at the Neuro-Immune Crosstalk in the Modulation of Inflammation, Asthma and Antimicrobial Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Current Understanding of the Role of Dendritic Cells and Their Co-Stimulatory Molecules in Generating Efficient T Cell Responses in Lepromatous Leprosy
Current Immunology Reviews (Discontinued) Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction of the Aging Innate Immune System
Current Immunology Reviews (Discontinued) Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Benefits of Structural Genomics for Drug Discovery Research
Infectious Disorders - Drug Targets Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery The Role of Intrinsically Disordered Regions in the Structure and Functioning of Small Heat Shock Proteins
Current Protein & Peptide Science Translating Enzymology into Metabolic Regulation: The Case of the 2- Oxoglutarate Dehydrogenase Multienzyme Complex
Current Chemical Biology Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors
Recent Patents on Anti-Infective Drug Discovery Pulmonary Vaccine Delivery Systems: A Novel Approach for Immunization
Current Drug Therapy Drug Repurposing for the Treatment of Staphylococcal Infections
Current Pharmaceutical Design RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science